Study examines Toxfin against T-2 toxin and fumonisin in layers

A newly published study in Animals examines whether Toxfin™ Dry can mitigate the effects of T-2 toxin and fumonisin exposure in laying hens, a question with practical relevance for veterinarians, nutritionists, and production teams managing chronic feed risk. Based on the abstract provided, the trial enrolled 480 Hy-Line W-36 hens at 25 weeks of age across six treatments and assessed not just performance and egg quality, but also intestinal morphometry, serum biochemistry, antioxidant status, and sphingolipid metabolism. That broader endpoint set stands out because it looks beyond visible production losses to biochemical and metabolic changes that may signal subclinical harm. The product itself is described by Kemin as a blend of activated or modified bentonite and sepiolite clays. (kemin.com)

The study lands in a well-established but still debated area of poultry nutrition. Mycotoxins remain a persistent feed issue, and in poultry they can reduce productivity, complicate disease management, and interact with nutritional status and vaccination response. Merck Veterinary Manual notes that mycotoxins in poultry can have additive or synergistic effects with infectious agents and nutritional deficiencies, which is one reason even moderate contamination can matter in commercial flocks. (merckvetmanual.com)

What makes this paper especially interesting is the toxin combination. T-2 toxin, a trichothecene, has long been associated with reduced egg production, poor shell quality, oral lesions, and altered serum chemistry in layers, while fumonisins are known for disrupting sphingolipid metabolism through ceramide synthase inhibition. Recent laying hen research has also focused on oxidative stress and lipid metabolism under combined Fusarium toxin exposure, suggesting that production metrics alone may miss meaningful biological effects. (mdpi.com)

That said, the binder story is nuanced. A 2022 review on mycotoxin binders concluded that binder performance depends heavily on the toxin involved, and that results should guide product selection based on the predominant contaminants present. Another review found clay binders are typically most reliable against aflatoxins, with more variable efficacy against fumonisins and T-2 toxin. In vitro work has similarly shown that bentonite and sepiolite can bind fumonisin and T-2 toxin, but generally at lower rates than aflatoxin, while formulation changes can improve performance. In other words, this new paper matters less as a broad endorsement of “clays” and more as product-specific evidence for one bentonite-sepiolite formulation under one challenge model. (pmc.ncbi.nlm.nih.gov)

There’s also a regulatory angle worth noting. In the European Union, bentonite has long been authorized for certain feed uses, including as a substance for reduction of aflatoxin B1 contamination, with specific use restrictions in poultry, including cautions around simultaneous use with some coccidiostats and macrolides at certain inclusion levels. Sepiolite also has EU authorizations as a feed additive in technological functions. Those authorizations don’t by themselves prove efficacy against every toxin combination, but they do help explain why bentonite- and sepiolite-based products remain widely used in feed programs. (eur-lex.europa.eu)

Why it matters: For veterinary professionals, the practical question is whether a binder meaningfully reduces health and production risk when contamination is real but not always obvious. If the full paper shows improvements in serum biochemistry, oxidative stress markers, or sphingolipid endpoints alongside production measures, that would strengthen the case for using targeted mitigation tools earlier, before a flock shows overt losses. It could also help veterinarians frame conversations with pet parents and food-animal clients alike around feed quality, ingredient sourcing, and the limits of relying on visible signs alone. Still, the broader literature supports a cautious reading: binders are one tool, not a substitute for ingredient testing, storage control, and a wider mycotoxin risk-management plan. (merckvetmanual.com)

Industry perspective appears to be moving in the same direction. Kemin’s own technical materials position Toxfin™ Dry as more than a simple aflatoxin binder, emphasizing clay processing and formulation as factors that may expand binding performance. Independent recent layer studies with other clay-based binders also suggest partial recovery in feed intake, egg production, egg quality, or mineral balance under mycotoxin challenge, though not always complete normalization. That pattern reinforces a realistic takeaway for clinicians and nutrition advisers: mitigation is possible, but expectations should stay grounded in the specific toxins, doses, and product tested. (kemin.com)

What to watch: The next step is the full dataset: inclusion rate, challenge dose, which endpoints improved significantly, and whether the sphingolipid findings translate into a clearer biomarker strategy for monitoring fumonisin exposure in commercial layer flocks. Longer term, field validation under commercial feed variability will matter more than a single controlled trial. (mdpi.com)